Clinical Trials Logo

Clinical Trial Summary

Vitamin D in the diet undergoes changes in the liver and kidneys to several forms. Patients suffering from disorders with Vitamin D resistance are unable to absorb calcium from food. Patients diagnosed with these disorders will be evaluated and treated with high doses of another form of Vitamin D (1,25-dihydroxyvitamin D3). Patients will be monitored and observed throughout the study to avoid experiencing side effects from the medication.


Clinical Trial Description

Patients with extreme resistance to 1,25-dihydroxyvitamin D will be evaluated and treated with high doses of 1,25-dihydroxyvitamin D3.

Plan: In previously untreated patients the study will be divided into a control and one or more treatment periods. During the control period, parathyroid status will be assessed by parameters nos. 1& 2 (below). In previously treated patients maintenance vitamin D will be gradually replaced with 1,25(OH)2D3. This will be accomplished by withdrawal of vitamin D and institution of 1,25(OH)2D3 when the serum calcium shows a downward trend.

1,25(OH)2D3 as 0.25 or 0.5 ug capsules (though IND 20,889) or as a solution of I microgram per ml will be administered orally. In most cases, because of consideration of time and expense, the cooperation of the patient's local physician will be enlisted. The following will be monitored:

1. Serum calcium, phosphorus,alkaline phosphatase,creatinine at twice weekly intervals. After a maintenance dose has been established, this will be decreased to a monthly, and subsequently 3-6 monthly interval.

2. Urine calcium, phosphorus,creatinine and cAMP before therapy and, when appropriate, during therapy.

The dose of 1,25(OH)2D3 will be 0.125 to 50.0 ug/day. Serum calcium will not be allowed to rise above the normal range (2.0 -2.4 mM at NIH). Should hypercalcemia occur, appropriate treatment will be initiated and the drug dosage will be decreased. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00001151
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase Phase 2
Start date March 1976
Completion date October 2009

See also
  Status Clinical Trial Phase
Completed NCT02892253 - Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia N/A
Completed NCT05043584 - Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions N/A
Recruiting NCT05885256 - Clinical Assessment of Low Calcium In traUMa (CALCIUM)
Recruiting NCT04160637 - Is There Benefit From Early Postoperative PTH Monitoring?
Completed NCT00506103 - The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT04012476 - Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy Phase 4
Recruiting NCT05586529 - Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia N/A
Completed NCT01868750 - Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia Phase 2
Completed NCT00668200 - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Phase 4
Terminated NCT00623974 - Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia Phase 2
Completed NCT00630214 - Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Phase 2
Not yet recruiting NCT03685877 - Hypocalcemia in Infants and Children
Completed NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Phase 3
Not yet recruiting NCT03063060 - The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy N/A
Not yet recruiting NCT04304573 - Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
Recruiting NCT05216419 - Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy Phase 4
Recruiting NCT04775381 - Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation Phase 3
Active, not recruiting NCT01632514 - Vitamin D Deficiency and Postoperative Hypocalcemia Phase 4
Recruiting NCT05260255 - Effect of Vitamin D Supplement on Disease Activity in SLE N/A